Table 2. Gender-stratified frequencies of malignancies and age-standardized incidence rates weighted for China (ASIRC) and for the world (ASIRW), 2008 to 2011.
| Malignancy Site/Type (ICD-O-3 Code) | Males, per 100,000 | Females, per 100,000 | ||||
|---|---|---|---|---|---|---|
| N | ASIRCa (CI) | ASIRWb (CI) | N | ASIRCa (CI) | ASIRWb (CI) | |
| All Cancers | 2,808 | 776.4 (742.1–810.6) | 881.7 (839.6–923.7) | 1,011 | 486.5 (436.4–536.6) | 508.9 (454.0–563.7) |
| All (Excluding Ill-defined/Unspecified) | 2,524 | 691.8 (659.7–724.0) | 782.7 (743.3–822.0) | 898 | 427.4 (380.5–474.2) | 446.0 (394.7–497.3) |
| Ill-defined/Unspecified | 284 | 84.6 (72.8–96.3) | 99.0 (84.2–113.9) | 113 | 59.2 (41.5–76.8) | 62.8 (43.5–82.1) |
| AIDS-Defining Cancers (all lymphomasc) | ||||||
| Kaposi sarcoma (9140) | 132 | 23.9 (18.9–28.8) | 23.9 (18.5–29.2) | 39 | 14.2 (9.0–19.4) | 13.9 (8.5–19.2) |
| Lymphomac (959, 965) | 299 | 63.1 (54.6–71.7) | 65.8 (56.3–75.4) | 117 | 48.0 (32.7–63.2) | 48.8 (32.3–65.2) |
| Cervical (C53) | - | - | - | 128 | 47.6 (38.3–57.0) | 48.0 (38.3–57.8) |
| Non-AIDS-Defining Cancers (no lymphomasc) | ||||||
| Oral cavity (C00–C09) | 13 | 5.3 (2.1–8.4) | 6.6 (2.3–10.8) | 4 | 1.9 (0.0–3.9) | 2.0 (0.0–4.2) |
| Nasopharynx (C11) | 38 | 11.0 (7.1–15.0) | 12.0 (7.6–16.3) | 9 | 3.8 (1.1–6.6) | 4.3 (1.1–7.4) |
| Other head and neck (C12–C14, C30–C32) | 47 | 13.8 (9.1–18.6) | 15.9 (10.0–21.7) | 17 | 7.6 (3.3–11.8) | 8.0 (3.4–12.7) |
| Esophagus (C15) | 78 | 25.3 (19.0–31.7) | 29.0 (21.4–36.7) | 19 | 14.8 (1.8–27.9) | 16.1 (1.7–30.4) |
| Stomach (C16) | 137 | 44.1 (35.6–52.6) | 52.6 (41.6–63.5) | 60 | 47.8 (24.2–71.4) | 51.4 (25.5–77.3) |
| Colon and rectum (C18–20) | 121 | 34.4 (27.3–41.5) | 39.2 (30.5–47.9) | 32 | 22.0 (11.0–33.0) | 23.1 (11.3–34.8) |
| Anus (C21) | 2 | 0.2 (0.0–0.5) | 0.2 (0.0–0.4) | 0 | - | - |
| Liver (C22) | 539 | 145.7 (131.0–160.3) | 160.8 (143.6–178.0) | 84 | 39.2 (27.4–51.0) | 41.4 (28.7–54.2) |
| Other digestive system (C23, C24, C26) | 6 | 1.8 (0.2–3.4) | 2.6 (0.0–5.3) | 1 | 0.7 (0.0–2.2) | 0.9 (0.0–2.6) |
| Pancreas (C25) | 41 | 12.0 (7.8–16.3) | 14.2 (8.8–19.5) | 2 | 5.0 (0.0–14.3) | 6.4 (0.0–18.6) |
| Lung (C34) | 713 | 226.0 (206.7–245.4) | 266.3 (241.8–290.8) | 140 | 66.8 (52.5–81.1) | 71.3 (55.7–86.9) |
| Mediastinum and pleura (C38) | 4 | 0.7 (0.0–1.5) | 0.7 (0.0–1.5) | 2 | 0.5 (0.0–1.3) | 0.5 (0.0–1.1) |
| Bone (C40) | 11 | 4.2 (1.3–7.0) | 5.3 (1.4–9.2) | 2 | 0.9 (0.0–2.1) | 1.0 (0.0–2.5) |
| Skin (C44) | 17 | 4.6 (2.1–7.2) | 5.0 (2.2–7.9) | 9 | 3.2 (1.0–5.3) | 3.2 (1.0–5.5) |
| Soft tissue (C47–C49) | 5 | 1.1 (0.0–2.3) | 1.1 (0.0–2.5) | 7 | 2.1 (0.5–3.7) | 2.1 (0.5–3.7) |
| Breast (C50) | 2 | 0.3 (0.0–0.8) | 0.3 (0.0–0.8) | 31 | 13.6 (7.0–20.2) | 14.1 (7.1–21.2) |
| Vagina and vulva (C51, C52) | - | - | - | 2 | 0.7 (0.0–1.7) | 0.7 (0.0–1.8) |
| Corpus uteri (C54) | - | - | - | 48 | 24.9 (10.8–39.0) | 26.2 (10.9–41.6) |
| Ovary and other female genital tissue (C55–C58) | - | - | - | 5 | 1.7 (0.2–3.1) | 1.7 (0.1–3.4) |
| Penis (C60) | 6 | 2.1 (0.2–3.9) | 2.4 (0.3–4.5) | - | - | - |
| Prostate (C61) | 9 | 4.3 (1.3–7.3) | 6.1 (1.7–10.5) | - | - | - |
| Other male genital (C62, C63) | 5 | 1.1 (0.0–2.5) | 1.2 (0.0–2.6) | - | - | - |
| Kidney (C64) | 10 | 2.5 (0.5–4.5) | 2.9 (0.4–5.3) | 2 | 0.6 (0.0–1.5) | 0.6 (0.0–1.5) |
| Other urinary system (C65–C68) | 3 | 0.8 (0.0–1.8) | 0.9 (0.0–2.0) | 0 | - | - |
| Bladder (C67) | 9 | 3.8 (1.1–6.6) | 5.6 (1.2–9.9) | 1 | 0.7 (0.0–2.2) | 0.9 (0.0–2.6) |
| Eye (C69) | 4 | 1.1 (0.0–2.4) | 1.1 (0.0–2.6) | 3 | 1.1 (0.0–2.5) | 1.2 (0.0–2.6) |
| Brain and CNS (C70, C71) | 216 | 45.5 (38.2–52.8) | 47.4 (39.2–55.6) | 105 | 43.0 (28.5–57.6) | 43.0 (27.3–58.7) |
| Thyroid (C73) | 2 | 0.4 (0.0–1.0) | 0.4 (0.0–1.0) | 0 | - | - |
| Multiple myeloma (C90) | 4 | 2.0 (0.0–4.0) | 2.3 (0.0–4.6) | 1 | 0.4 (0.0–1.3) | 0.5 (0.0–1.6) |
| Melanoma (872) | 1 | 0.3 (0.0–0.9) | 0.4 (0.0–1.1) | 0 | - | - |
| Leukemia (981) | 50 | 10.3 (6.8–13.8) | 10.7 (6.7–14.6) | 28 | 14.4 (6.1–22.6) | 14.6 (5.9–23.4) |
ICD-O-3: International Classification of Disease for Oncology [32], 3rd Edition, ASIRC: age-standardized incidence rate for China, ASIRW: age-standardized incidence rate for the world, CI: 95% confidence interval, CNS: central nervous system
aASIRC is per 100,000, weighted by Chinese population in 2010 according to national census data [33], and CI calculated based on an assumed Poisson distribution
bASIRW is per 100,000, weighted by the World Health Organization’s world standard population data for 2002 to 2025 [34], and CI calculated based on an assumed Poisson distribution
cBecause approximately half of lymphoma records did not specify Hodgkin or Non-Hodgkin lymphoma, combined observed and expected lymphoma figures were calculated